These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 27713291)
1. Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2. Brod SA Pharmaceuticals (Basel); 2010 Apr; 3(4):1108-1121. PubMed ID: 27713291 [TBL] [Abstract][Full Text] [Related]
2. Ingested type I interferon: state of the art as treatment for autoimmunity. Brod SA Exp Biol Med (Maywood); 2002 Dec; 227(11):981-8. PubMed ID: 12486207 [TBL] [Abstract][Full Text] [Related]
3. Ingested type I interferon: a potential treatment for autoimmunity. Brod SA J Interferon Cytokine Res; 2002 Dec; 22(12):1153-66. PubMed ID: 12581487 [TBL] [Abstract][Full Text] [Related]
4. Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT system. Brod SA J Interferon Cytokine Res; 1999 Aug; 19(8):841-52. PubMed ID: 10476927 [TBL] [Abstract][Full Text] [Related]
5. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis. Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030 [TBL] [Abstract][Full Text] [Related]
6. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Rother KI; Brown RJ; Morales MM; Wright E; Duan Z; Campbell C; Hardin DS; Popovic J; McEvoy RC; Harlan DM; Orlander PR; Brod SA Diabetes Care; 2009 Jul; 32(7):1250-5. PubMed ID: 19564474 [TBL] [Abstract][Full Text] [Related]
7. Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS. Brod SA; Lindsey JW; Vriesendorp FS; Ahn C; Henninger E; Narayana PA; Wolinsky JS Neurology; 2001 Sep; 57(5):845-52. PubMed ID: 11552015 [TBL] [Abstract][Full Text] [Related]
9. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. Brod SA; Kerman RH; Nelson LD; Marshall GD; Henninger EM; Khan M; Jin R; Wolinsky JS Mult Scler; 1997 Feb; 3(1):1-7. PubMed ID: 9160341 [TBL] [Abstract][Full Text] [Related]
10. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment]. Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835 [TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503 [TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
13. Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes. Brod SA; Atkinson M; Lavis VR; Brosnan PG; Hardin DS; Orlander PR; Nguyen M; Riley WJ J Interferon Cytokine Res; 2001 Dec; 21(12):1021-30. PubMed ID: 11798459 [TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Link J Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782 [TBL] [Abstract][Full Text] [Related]
15. Elevated IFN-alpha/beta levels in a streptozotocin-induced type I diabetic mouse model promote oxidative stress and mediate depletion of spleen-homing CD8+ T cells by apoptosis through impaired CCL21/CCR7 axis and IL-7/CD127 signaling. Mahmoud MH; Badr G; Badr BM; Kassem AU; Mohamed MS Cell Signal; 2015 Oct; 27(10):2110-9. PubMed ID: 26192098 [TBL] [Abstract][Full Text] [Related]
16. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
17. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Skurkovich S; Boiko A; Beliaeva I; Buglak A; Alekseeva T; Smirnova N; Kulakova O; Tchechonin V; Gurova O; Deomina T; Favorova OO; Skurkovic B; Gusev E Mult Scler; 2001 Oct; 7(5):277-84. PubMed ID: 11724442 [TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. Milanés-Virelles MT; García-García I; Santos-Herrera Y; Valdés-Quintana M; Valenzuela-Silva CM; Jiménez-Madrigal G; Ramos-Gómez TI; Bello-Rivero I; Fernández-Olivera N; Sánchez-de la Osa RB; Rodríguez-Acosta C; González-Méndez L; Martínez-Sánchez G; López-Saura PA; BMC Infect Dis; 2008 Feb; 8():17. PubMed ID: 18267006 [TBL] [Abstract][Full Text] [Related]
20. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]